Videos
Clinical Conversations by Experts
View all

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer
- Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6
- Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer - Session 2 Case 1 - H Jacene, A Kibel, P Nguyen, & A Morgans View all Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer videos

Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer
- Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
- The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar
- Sequencing Radiopharmaceuticals: Efficacy and Safety Data of Radium-223 Followed by Lutetium-177-PSMA in the RALU Study - Oliver Sartor
- Radiopharmaceuticals in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans View all Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer videos

ASCO GU 2023
- Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial - Michiel Van der Heijden
- The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
- Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi View all ASCO GU 2023 videos

Artificial Intelligence in Prostate Cancer 2022
- Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng
- Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model - Jonathan Tward
- Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer - Daniel Spratt View all Artificial Intelligence in Prostate Cancer 2022 videos
Featured Videos

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
PCF 2022
Prostate cancer genomic classifier Videos
Latest Videos
Bladder Cancer Videos

DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist

AUA 2023 Conference Highlights
- AUA Urology Advocacy Summit 2023: Need to Know: Inflation Reduction Act of 2022 and its Impact on Urology
- AUA Urology Advocacy Summit 2023: State Advocacy: Chaperone Rules and Criminalization of Physician Care
- AUA Urology Advocacy Summit 2023: Breaking Down Barriers to PSA Screenings
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles

Advanced Prostate Cancer
- Radiotherapy in Prostate Cancer: Utilization in the Metastatic Setting
Written by Rashid Sayyid, MD MSc & Zachary Klaassen, MD MSc
- The Current Landscape of PSMA PET Imaging in Prostate Cancer: Advanced Prostate Cancer
Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc

mHSPC
- Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous Low Volume mHSPC
Written by Rashid K. Sayyid, MD MSc and Zachary Klaassen, MD MSc
- Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous High Volume mHSPC
Written by Rashid K. Sayyid, MD MSc and Zachary Klaassen, MD,MSc
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Bladder Cancer Detection
New Study Publication Reinforces the Clinical Benefits of Blue Light Cystoscopy in the ASC Setting; Supports Ongoing Initiatives to Further Improve Reimbursement
Reno, Nevada (UroToday.com) -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?” in Urologic Oncology this week. The research objective was to quantify the clinical and economic impact of the incorporation of BLC in the management of NMIBC in ambulatory surgical centers (ASCs) considering 2022 Center for Medicare Services (CMS) patient-physician coverage and reimbursement.
Read More
Read More
Clinical Application And Utility Of PYLARIFY
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain. Read More
ARAMIS Trial
Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit. Read More
ARASENS Trial
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.
Read More
Read More
VISION Trial
FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting. Read More